恩替卡韦与替诺福韦对乙型肝炎病毒相关肝细胞癌根治性肝切除术后预后的比较
该研究基于2011—2016年台湾癌症登记与全民健康保险研究数据库,纳入7107例乙型肝炎病毒相关肝细胞癌根治性肝切除术后患者,25.3%术后使用恩替卡韦或替诺福韦。经倾向评分重叠加权后1797例(恩替卡韦1365例、替诺福韦432例)纳入分析,两组复发风险(HR 0.91,95%CI 0.69-1.19)与全因死亡风险(HR 0.67,95%CI 0.42-1.07)均无显著差异。
要点
- 根治性肝切除术后使用替诺福韦与恩替卡韦的复发风险相似(HR 0.91,95%CI 0.69-1.19)。
- 两组全因死亡风险无显著差异(HR 0.67,95%CI 0.42-1.07)。
- 早期复发(<2年)与晚期复发(≥2年)在两组间均无显著差异。
核心结论
- 在乙型肝炎病毒相关肝细胞癌根治性肝切除术后患者中,替诺福韦与恩替卡韦在复发和总生存方面显示相似的健康获益。
研究设计与样本
- 基于2011—2016年台湾癌症登记与台湾全民健康保险研究数据库链接数据的分析。
- 识别7107例乙型肝炎病毒相关肝细胞癌根治性肝切除术后患者,其中25.3%术后使用恩替卡韦或替诺福韦。
- 经倾向评分重叠加权后纳入1797例患者,恩替卡韦组1365例、替诺福韦组432例。
- 采用Cox比例风险模型比较恩替卡韦与替诺福韦对复发和总生存的疗效。
主要发现
- 肝切除术后每100人年复发率恩替卡韦组为14.87、替诺福韦组为9.25。
- 替诺福韦组与恩替卡韦组的复发风险相似(HR 0.91,95%CI 0.69-1.19;p=0.479)。
- 替诺福韦组与恩替卡韦组的全因死亡风险相似(HR 0.67,95%CI 0.42-1.07;p=0.091)。
- 早期复发(<2年)与晚期复发(≥2年)在替诺福韦组与恩替卡韦组间均无显著差异。
- 亚组分析和敏感性分析显示结果一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is still controversy about whether tenofovir disoproxil fumarate (TDF) and entecavir (ETV) have different effects on the outcomes of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). AIMS: The aim of this study was to compare the prognoses between ETV and TDF treatment among patients with HBV-related HCC after hepatectomy. METHODS: An analysis was done on data from the Taiwan Cancer Registry, which was linked to Taiwan National Health Insurance Research Database, for the years 2011-2016. We identified 7107 patients with HBV-related HCC after curative hepatectomy, and 25.3% of them used ETV or TDF after surgery. After propensity score overlap weighting, 1797 patients treated with ETV (n = 1365) or TDF (n = 432) were included for analyses. Cox proportional hazards models were used to compare the efficacy of ETV and TDF for recurrence and overall survival (OS). RESULTS: After hepatectomy, the recurrence rate per 100 person-years was 14.87 for the ETV group and 9.25 for the TDF group. The risk of recurrence was similar in the TDF group and the ETV group (HR [95% CI]: 0.91 [0.69-1.19; p = 0.479]), as was the risk of all-cause mortality (HR [95% CI]: 0.67 [0.42-1.07]; p = 0.091). When considering early recurrence (<2 years) and late recurrence (≧2 years), the TDF and ETV groups showed no significant differences. Subgroup analyses and sensitivity analyses demonstrated consistent results. CONCLUSION: Both TDF and ETV showed similar health benefits in terms of recurrence and OS in patients with HBV-related HCC patients after hepatectomy.
引用
- Kao WY, Tan EC, Lee HL, et al. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy. Aliment Pharmacol Ther. 2023. PMID: 36914943. doi:10.1111/apt.17438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。